GE Healthcare, an integral part of General Electric Company ( GE ), recently announced a strategic partnership with Real Time Medical, a developer of workflow management software solutions, to improve clinical outcomes and productivity in the pathology department.
GE Healthcare offers Omnyx Integrated Digital Pathology (IDP) ??? a fully integrated, scalable digital pathology solution designed for pathologists. It helps single and multi-site pathology departments to benefit from improved research performance, increased efficiencies and provides greater access to peers in the field.
Real Time Medical's DiaShare workflow management platform is a software suite offering multi-disciplinary digital imaging solution. By offering Omnyx IDP and DiaShare as a combined solution, GE Healthcare and Real Time Medical aim to empower pathologists to improve speed and accuracy of diagnosis. This new solution connects pathologists and other clinicians with innovative technology and helps them remove manual processes and delays to ensure a seamless work flow. Together, these solutions optimize workflow, utilize resources effectively, increase reporting productivity and improve the accuracy of service in complicated diagnostic imaging networks.
General Electric is one of the most diversified technologies and financial service corporations in the world. The company's segments include Power & Water, Oil & Gas, Energy Management, Aviation, Healthcare, Transportation, Home & Business Solutions, and GE Capital. GE Healthcare has expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceutical manufacturing technologies.
General Electric currently has a Zacks Rank #3 (Hold). Other stocks that look promising and are worth a look now include CLARCOR Inc ( CLC ), Icahn Enterprises, L.P. ( IEP ) and Noble Group Limited ( NOBGY ), each carrying a Zacks Rank #1 (Strong Buy).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.